Latest News

PolyNovo (ASX:PNV) has announced that Professor Toby Coates AO, the director of Beta Cell Technologies, has presented the results of the company's NovoSorb and its potential role in treating and managing Type 1 diabetes.

EnGeneIC has announced the dosing of the first patient in its open-label, multicentre, Phase I/IIa clinical trial at Mater Hospital in Sydney.

Prime Minister Anthony Albanese has appointed Senator Tim Ayres to the industry, innovation and science portfolios.

PolyNovo (ASX:PNV) has announced that its NovoSorb MTX (4 mm, 6 mm) has received TGA clearance, following the regulator's clearance of the 2 mm product in March. 

A team of Melbourne scientists has been backed by the Australian Government’s Medical Research Future Fund Stem Cell Therapies Mission to support their development of potential new medicines to treat dementia.

Radiopharm Theranostics (ASX:RAD) has achieved a milestone in its ongoing clinical development program for its radiotherapeutic asset, 177Lu-RAD204.

Clinical-stage company Tryptamine Therapeutics (ASX:TYP) has announced the appointment of Herwig Janssen as its non-executive chairman.

Algorae Pharmaceuticals (ASX:1AI) has agreed with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI-predicted drug synergies through high-throughput screening.

Neuren Pharmaceuticals (ASX:NEU) has updated investors on the first quarter 2025 financial results announcement and conference call of its partner Acadia Pharmaceuticals.

LTR Pharma (ASX:LTP) has entered a collaborative development agreement with Strategic Drug Solutions to co-develop OROFLOW, a novel intranasal spray targeting Oesophageal Motility Disorders.

Percheron Therapeutics (ASX:PER) has lodged a prospectus for a pro-rata non-renounceable bonus offer of unquoted options to acquire loyalty options to eligible shareholders.

OncoSil Medical managing director and CEO Nigel Lange said, “The results of this important analysis highlight the superiority of the OncoSil device compared to Stereotactic Body Radiation Therapy, which is considered to be the best available system for delivering external beam radiotherapy to patients with locally advanced pancreatic cancer."